Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 33,783

Document Document Title
WO/2021/069891A1
The invention provides an agent for the treatment or prevention of viral infection in a subject. The agent is preferably a compound of Formula (I) or (la) wherein R1-R4, A and B are as defined herein. Also provided are pharmaceutical com...  
WO/2021/072156A1
Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the...  
WO/2021/070658A1
Provided is a method for producing a cyclopentane compound, the method allowing easy synthesis of a cyclopentane compound in a diastereoselective manner and, as necessary, in an enantioselective manner, the compound having multiple asymm...  
WO/2021/070963A1
The present invention provides a compound for further improving the performance of an organic EL element, an organic electroluminescent element in which element performance is further improved, and an electronic device that includes such...  
WO/2021/070964A1
Provided are: a compound which further improves the performance of organic EL elements; an organic electroluminescent element which has performance that is further improved; and an electronic device which includes such an organic electro...  
WO/2021/071438A1
A method for producing a cannabinoid by contacting cannabigerolic acid with a cannabinoid synthase orthologue. The cannabinoid synthase orthologue is from an organism other than Cannabis sativa. Also disclosed is a recombinant cell of Sa...  
WO/2021/070965A1
Provided are a compound that further improves the performance of organic EL elements, an organic electroluminescent element having further improved element performance, and an electronic device including such an organic electroluminescen...  
WO/2021/069184A1
The present invention relates to a compound of formula (I), to the use thereof in electronic devices, to methods for producing said compound, and to electronic devices containing the compound.  
WO/2021/072300A1
Disclosed herein are phospholipid ether (PLE) molecules. Further provided are phospholipid-flavagline conjugates. The phospholipid-flavagline conjugate may include a PLE conjugated to a flavagline via a linker. Further provided herein ar...  
WO/2021/067815A1
Chromophores with large hyperpolarizabilities, films with electro-optic activity comprising the chromophores, and electro-optic devices comprising the chromophores are disclosed.  
WO/2021/065893A1
The purpose of the present invention is to provide a novel low-molecular-weight compound that exhibits agonistic activity on an orexin receptor and is expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the li...  
WO/2021/064189A2
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...  
WO/2021/064530A1
Described herein is a dicarboxylic acid compound of formula (I): Wherein: R3 comprises an aryl group, R2 is an alkylene group comprising 1 to 6 carbon atoms, n is 0 or 1, R1 is H or CH3, and X is S or NZ, wherein Z is H, an alkyl group c...  
WO/2021/061545A1
A method is provided for synthesizing an aromatic carboxylic acid compound comprising providing an aromatic compound or an aromatic compound with at least one carboxylic group; providing a metal hydroxide and at least one carboxylate to ...  
WO/2021/059086A1
Provided is a novel organic compound. Provided is an organic compound represented by general formula (G1). (In general formula (G1), either A or B is a group represented by the general formula (g1). Furthermore, the other of A and B, R1...  
WO/2021/060723A1
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an ele...  
WO/2021/061887A1
A process is provided for making a polymer comprising providing a mixture of at least one furandicarboxylic acid, at least one diol, and at least one C2-C3 dicarboxlic acid, ester derivatives of C2-C3 dicarboxylic acid, hydroxy fatty aci...  
WO/2021/060239A1
A compound represented by formula (1) below (wherein the various symbols in the formula are as defined in the description) provides an organic electroluminescent element having improved element performance.  
WO/2021/055849A1
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...  
WO/2021/055506A1
Described herein are compounds that act as antimicrobial agents, compositions comprising these compounds, and methods of their use in to treating infections caused by Helicobacter pylori (H. pylori) or killing or inhibititing the growth ...  
WO/2021/032004A9
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...  
WO/2021/054714A1
The present application provides: a heterocyclic compound capable of significantly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; and an organic light-emitting de...  
WO/2021/054804A1
The present invention pertains to a pharmaceutical or food composition for preventing or treating proteopathies, the pharmaceutical or food composition containing a novel p62 ligand compound represented by chemical formula 1, or a stereo...  
WO/2021/049654A1
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), a first light emitting layer (51) and a second light emitting layer (52) that is arranged between the first light emitting laye...  
WO/2021/047627A1
A compound as shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.  
WO/2021/049662A1
This organic electroluminescence element (1) includes a positive electrode (3), a negative electrode (4), a first light emitting layer (51), and a second light emitting layer (52) disposed between the first light emitting layer (51) and ...  
WO/2021/046996A1
The present invention provides a method for improving synthesis efficiency of 5-hydroxymethylfurfural. A synthesis system of 5-hydroxymethylfurfural comprises an organic solvent. In a reaction process, the organic solvent is first prehea...  
WO/2021/046995A1
Provided is a method for preparing 5-hydroxymethyl furfural by catalyzing a hexose with an ionic liquid. With the acidic ionic liquid serving as a catalyst and the hexose serving as a raw material, 5-hydroxymethyl furfural is prepared by...  
WO/2021/049663A1
An organic electroluminescence element (1) that has a positive electrode (3), a negative electrode (4), a first light-emitting layer (51), and a second light-emitting layer (52) that is arranged between the first light-emitting layer (51...  
WO/2021/049472A1
Provided is a compound that has a high sensitivity and is highly soluble in a solvent. The compound is represented by general formula (X-1). [Chemical formula 1] (In formula (X-1), each R0 is independently a hydrogen atom, a dissociable ...  
WO/2021/050992A1
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.  
WO/2021/045153A1
Provided is a method for producing gamma-butyrolactone, said method including a reaction step in which a raw material composed of one or both of 2-hydroxytetrahydrofuran and 4-hydroxybutyraldehyde and a catalyst containing copper and an ...  
WO/2021/045927A1
A process for preparing 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) by oxidizing various furcates in the presence of a catalyst containing cobalt, manganese, and bromine, and a solvent while simultaneously removing water vapor from...  
WO/2021/042410A1
Disclosed are a selective butyrylcholinesterase inhibitor having general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof. By testing the efficacy of treatment of Alzheimer's disea...  
WO/2021/045207A1
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...  
WO/2021/045527A1
The present invention pertains to: a diol compound capable of producing a polycarbonate having excellent mechanical properties, weather resistance, hardness, heat resistance, transparency, and impact resistance; a polycarbonate produced ...  
WO/2021/043194A1
Provided are a halogenated tetracyclic triterpene derivative as represented by general formula A, a preparation and an application thereof. R 1 is a halogen, R 2 is H, and the halogen is selected from fluorine, chlorine, bromine or iodin...  
WO/2021/016220A3
A method is provided of preparing a compound of formula II: where: R1 and R2 are independently selected from -CH2OR', -CHO, -COOR' and -H, provided that R1 and R2 are not both -H; and R' is selected from -H and C1-6 hydrocarbyl groups, f...  
WO/2021/036514A1
A novel PPAR γ/δ dual agonist as described in general formula (I), a preparation method thereof and an application of a pharmaceutical composition containing a derivative in the preparation of a drug for prevention and/or treatment of ...  
WO/2021/031999A1
The present invention belongs to the field of medicine, and specifically relates to a prodrug of mycophenolic acid and a method for preparation thereof. The structural formula thereof is as shown in formula I; in comparison with mycophen...  
WO/2021/032004A1
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...  
WO/2021/030091A1
The present disclosure relates to compounds, compositions and supplements that are capable of treating obesity. The disclosure further relates to methods of treating obesity in a subject in need thereof.  
WO/2021/030773A1
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing ...  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/023765A1
Furan, thiophene or y-lactam sesterterpene tetronic acids of formula (I), process for their preparation or for isolation from marine sponges, as well as to pharmaceutical compositions comprising them and their use in pharmacy, in particu...  
WO/2021/023914A1
A composition and a method for use in suppressing growth and/or proliferation of cancer cells in vivo and in vitro is provided. The composition includes an alcoholic lignan extract prepared from coniferous species optionally in combinati...  
WO/2021/021909A1
Disclosed are compounds and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such a compound, salt, or prodrug. Also disclosed are metho...  
WO/2021/021840A1
There is provided a compound having Formula (I) In Formula I = Ar1 is a hydrocarbon aryl group, a heteroaryl group, or a substituted derivative thereof; and Q has Formula (Q1), (Q2), or (Q3) The variables are described in detail herein.  
WO/2021/020429A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.  
WO/2021/019942A1
Provided is a monomer that imparts higher heat resistance to a resin while improving solubility in an organic solvent, hydrolyzability, and solubility in water after hydrolysis. This resin for photoresist contains a polymerization unit r...  

Matches 1 - 50 out of 33,783